Abstract
Somatostatin (somatotropin release inhibitory factor; SRIF) peptides are widely distributed throughout the mammalian body and act through a family of genetically distinct, guanine nucleotide regulatory protein coupled (Gprotein- coupled), cell surface receptors (sst1-5). Compelling evidence shows that SRIF and SRIF peptidyl analogs modulate vascular function, with actions upon smooth muscle and endothelium. SRIF receptors are known to exist in the carotid endothelium, a principal target for the pro-inflammatory cascade that accompanies coronary artery disease. SRIF- 14 and SRIF analogs are anti-inflammatory but the molecular mechanism involved remains unclear. Since crucial steps in the endothelial inflammation response include endothelial activation by cytokines, adhesion molecule expression and cellmonocyte interactions, peptide agents that inhibit these steps might provide a novel strategy for reducing vascular inflammation. SRIF, acting through its cognate receptors, modulates a variety of intracellular effectors that are linked to inflammation including phosphotyrosine phosphatases, the extracellular regulated protein kinase 1 and 2 (ERK1/2) cascade, adenylyl cyclase and endothelial nitric oxide synthase. Directly or indirectly, SRIF also functions to inhibit endothelial cell proliferation and induce apoptosis. A detailed understanding of SRIF actions could provide a rational basis for using SRIF ligands in controlling vascular inflammation and inhibiting cytokine signaling, critical events in atherogenesis.
Keywords: somatostatin, endothelium, vasculature, proliferation, inflammation, somatostatin receptors, somatostatin analogs
Current Vascular Pharmacology
Title: Somatostatin: A Hormone for the Heart?
Volume: 3 Issue: 2
Author(s): Amy C. Badway and Allan D. Blake
Affiliation:
Keywords: somatostatin, endothelium, vasculature, proliferation, inflammation, somatostatin receptors, somatostatin analogs
Abstract: Somatostatin (somatotropin release inhibitory factor; SRIF) peptides are widely distributed throughout the mammalian body and act through a family of genetically distinct, guanine nucleotide regulatory protein coupled (Gprotein- coupled), cell surface receptors (sst1-5). Compelling evidence shows that SRIF and SRIF peptidyl analogs modulate vascular function, with actions upon smooth muscle and endothelium. SRIF receptors are known to exist in the carotid endothelium, a principal target for the pro-inflammatory cascade that accompanies coronary artery disease. SRIF- 14 and SRIF analogs are anti-inflammatory but the molecular mechanism involved remains unclear. Since crucial steps in the endothelial inflammation response include endothelial activation by cytokines, adhesion molecule expression and cellmonocyte interactions, peptide agents that inhibit these steps might provide a novel strategy for reducing vascular inflammation. SRIF, acting through its cognate receptors, modulates a variety of intracellular effectors that are linked to inflammation including phosphotyrosine phosphatases, the extracellular regulated protein kinase 1 and 2 (ERK1/2) cascade, adenylyl cyclase and endothelial nitric oxide synthase. Directly or indirectly, SRIF also functions to inhibit endothelial cell proliferation and induce apoptosis. A detailed understanding of SRIF actions could provide a rational basis for using SRIF ligands in controlling vascular inflammation and inhibiting cytokine signaling, critical events in atherogenesis.
Export Options
About this article
Cite this article as:
Badway C. Amy and Blake D. Allan, Somatostatin: A Hormone for the Heart?, Current Vascular Pharmacology 2005; 3 (2) . https://dx.doi.org/10.2174/1570161053586958
DOI https://dx.doi.org/10.2174/1570161053586958 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TNF-induced Lupus. A Case-Based Review
Current Rheumatology Reviews Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Acute Severe Arterial Hypertension: Therapeutic Options
Current Drug Targets Studies on Novel Pyridine and 2-pyridone Derivatives of N-arylpiperazine as α-adrenoceptor Ligands
Medicinal Chemistry Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry MEFV Mutation Carriers and Diseases Other than Familial Mediterranean Fever: Proved and Non-Proved Associations; Putative Biological Advantage
Current Drug Targets - Inflammation & Allergy Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Prognostic Parameters for Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke in an Asian Population
Current Neurovascular Research The Role of Estrogen and Estrogen-Related Drugs in Cardiovascular Diseases
Current Drug Metabolism Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile
Current Drug Safety Autoimmune Neuromuscular Disorders
Current Neuropharmacology IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Foreword: The Year in Review: Comments on Plants, Cyclodextrins, Microbiota, and Diabetes
Current Pharmaceutical Design New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Viral Encephalitis: Current Treatments and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews